Population pharmacokinetics of unbound ceftriaxone in a critically ill population

S.D. Meenks; J.L.M.L. le Noble; N.A. Foudraine; F. de Vries; K. Neef; P.K.C. Janssen

doi:10.5414/CP204181

Population pharmacokinetics of unbound ceftriaxone in a critically ill population

S.D. Meenks^*, J.L.M.L. le Noble, N.A. Foudraine, F. de Vries, K. Neef, P.K.C. Janssen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Department of Hospital Pharmacy, VieCuri Medical Center, Tegelseweg 210, 5912 BL Venlo, The Netherlands, partment 0.18 +/- 0.08 h-1. Dosing simulations predicted fT>4 mg /L of 88% (95% CI: 69 - 100%) for 2,000 mg ceftriaxone once daily and fT>4 mg /L of 100% (95% CI: 100 - 100%) both for 1,000 mg twice daily and continuous in-fusion of 2,000 mg daily. Conclusion: We de-veloped a reliable population PK model for unbound ceftriaxone in a critically ill popu-lation. Dosing simulations revealed fT>4 mg/L >= 60% for 1,000 mg twice daily and 2,000 mg once daily or by continuous infusion.

Original language	English
Pages (from-to)	373-383
Number of pages	11
Journal	International Journal of Clinical Pharmacology and Therapeutics
Volume	60
Issue number	9
DOIs	https://doi.org/10.5414/CP204181
Publication status	Published - 1 Sept 2022

Keywords

ceftriaxone -
pharmacokinetics
critically ill
pharmacokinetic modelling
&nbsp
free or unbound concentration
INTENSIVE-CARE-UNIT
BETA-LACTAM ANTIBIOTICS
CLINICAL PHARMACODYNAMICS
PROTEIN-BINDING
CEFEPIME
INFUSION
PROBABILITY
CEFTAZIDIME
MEROPENEM
PREDICT

Access to Document

10.5414/CP204181

Cite this

@article{9b4b21958c744befa1c12a8b9ef329b6,

title = "Population pharmacokinetics of unbound ceftriaxone in a critically ill population",

abstract = "Department of Hospital Pharmacy, VieCuri Medical Center, Tegelseweg 210, 5912 BL Venlo, The Netherlands, partment 0.18 +/- 0.08 h-1. Dosing simulations predicted fT>4 mg /L of 88% (95% CI: 69 - 100%) for 2,000 mg ceftriaxone once daily and fT>4 mg /L of 100% (95% CI: 100 - 100%) both for 1,000 mg twice daily and continuous in-fusion of 2,000 mg daily. Conclusion: We de-veloped a reliable population PK model for unbound ceftriaxone in a critically ill popu-lation. Dosing simulations revealed fT>4 mg/L >= 60% for 1,000 mg twice daily and 2,000 mg once daily or by continuous infusion.",

keywords = "ceftriaxone -, pharmacokinetics, critically ill, pharmacokinetic modelling, &nbsp, free or unbound concentration, INTENSIVE-CARE-UNIT, BETA-LACTAM ANTIBIOTICS, CLINICAL PHARMACODYNAMICS, PROTEIN-BINDING, CEFEPIME, INFUSION, PROBABILITY, CEFTAZIDIME, MEROPENEM, PREDICT",

author = "S.D. Meenks and {le Noble}, J.L.M.L. and N.A. Foudraine and {de Vries}, F. and K. Neef and P.K.C. Janssen",

note = "Funding Information: The authors thank Hai Holthuysen and Loes Simons, laboratory analysts at the Department of Hospital Pharmacy, VieCuri Medical Center, Venlo, for performing laboratory measurements. English language editing was performed by Editage (www.editage.com). This study was funded by the “Fonds Wetenschap en Innovatie VieCuri Medisch Centrum” (grant number not applicable) and received no external funding. Publisher Copyright: {\textcopyright}2022 Dustri-Verlag Dr. K. Feistle.",

year = "2022",

month = sep,

day = "1",

doi = "10.5414/CP204181",

language = "English",

volume = "60",

pages = "373--383",

journal = "International Journal of Clinical Pharmacology and Therapeutics",

issn = "0946-1965",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "9",

}

TY - JOUR

T1 - Population pharmacokinetics of unbound ceftriaxone in a critically ill population

AU - Meenks, S.D.

AU - le Noble, J.L.M.L.

AU - Foudraine, N.A.

AU - de Vries, F.

AU - Neef, K.

AU - Janssen, P.K.C.

N1 - Funding Information: The authors thank Hai Holthuysen and Loes Simons, laboratory analysts at the Department of Hospital Pharmacy, VieCuri Medical Center, Venlo, for performing laboratory measurements. English language editing was performed by Editage (www.editage.com). This study was funded by the “Fonds Wetenschap en Innovatie VieCuri Medisch Centrum” (grant number not applicable) and received no external funding. Publisher Copyright: ©2022 Dustri-Verlag Dr. K. Feistle.

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Department of Hospital Pharmacy, VieCuri Medical Center, Tegelseweg 210, 5912 BL Venlo, The Netherlands, partment 0.18 +/- 0.08 h-1. Dosing simulations predicted fT>4 mg /L of 88% (95% CI: 69 - 100%) for 2,000 mg ceftriaxone once daily and fT>4 mg /L of 100% (95% CI: 100 - 100%) both for 1,000 mg twice daily and continuous in-fusion of 2,000 mg daily. Conclusion: We de-veloped a reliable population PK model for unbound ceftriaxone in a critically ill popu-lation. Dosing simulations revealed fT>4 mg/L >= 60% for 1,000 mg twice daily and 2,000 mg once daily or by continuous infusion.

AB - Department of Hospital Pharmacy, VieCuri Medical Center, Tegelseweg 210, 5912 BL Venlo, The Netherlands, partment 0.18 +/- 0.08 h-1. Dosing simulations predicted fT>4 mg /L of 88% (95% CI: 69 - 100%) for 2,000 mg ceftriaxone once daily and fT>4 mg /L of 100% (95% CI: 100 - 100%) both for 1,000 mg twice daily and continuous in-fusion of 2,000 mg daily. Conclusion: We de-veloped a reliable population PK model for unbound ceftriaxone in a critically ill popu-lation. Dosing simulations revealed fT>4 mg/L >= 60% for 1,000 mg twice daily and 2,000 mg once daily or by continuous infusion.

KW - ceftriaxone -

KW - pharmacokinetics

KW - critically ill

KW - pharmacokinetic modelling

KW - &nbsp

KW - free or unbound concentration

KW - INTENSIVE-CARE-UNIT

KW - BETA-LACTAM ANTIBIOTICS

KW - CLINICAL PHARMACODYNAMICS

KW - PROTEIN-BINDING

KW - CEFEPIME

KW - INFUSION

KW - PROBABILITY

KW - CEFTAZIDIME

KW - MEROPENEM

KW - PREDICT

U2 - 10.5414/CP204181

DO - 10.5414/CP204181

M3 - Article

C2 - 35861497

SN - 0946-1965

VL - 60

SP - 373

EP - 383

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

IS - 9

ER -